–TACT2 will test chelation in heart attack patients with diabetes. The NIH has agreed to fund a second round of a highly controversial study testing the possible benefits of chelation therapy in heart attack patients with diabetes. The second Trial to Assess Chelation Therapy (TACT2), now recruiting patients at more than 100 clinical sites, is…
Second Trial Of Controversial Chelation Therapy Gains Crucial Early Support
The National Institutes of Health is giving money to support the planning of a second trial to test the potential role of chelation therapy in treating patients with myocardial infarction. The first Trial to Assess Chelation Therapy (TACT) was extremely controversial. It was funded by the NIH more than a dozen ago as part of an initiative to…
TACT Principal Investigator Reflects On A Long And Contentious Journey
In a fascinating and important blog post, Gervasio Lamas offers a deeply personal perspective on the long and contentious journey of the Trial to Assess Chelation Therapy (TACT), for which he was the principal investigator. Here are a few quotes from his post, but I can’t urge you strongly enough to read the entire post over…
TACT Substudy Suggests Possible Strong Benefit for Chelation in Diabetics
One year ago the results of the TACT trial were published in JAMA, sparking an enormous controversy over the propriety of publishing a trial suggesting that chelation therapy might be beneficial in people with cardiovascular disease. Chelation therapy has long been a staple of alternative medicine, but until the publication of TACT it had received no credit whatsoever in…
NIH Trial Gives Surprising Boost To Chelation Therapy
With a result that is likely to surprise and baffle much of the mainstream medical community, a large NIH-sponsored trial has turned up the first substantial evidence in support of chelation therapy for patients with coronary disease. Known as TACT (Trial to Assess Chelation Therapy), the highly controversial trial was presented today at the AHA by Gervasio…
Recent Comments